1 Expected Dates
PIPELINE
Obesity & liver diseases
Pemvidutide
(ALT-801)
(ALT-801)
MOMENTUM Obesity trial top line 48-wk results in Q4 2023
Pemvidutide
(ALT-801)
(ALT-801)
IMPACT Phase 2b NASH trial top line data in Q1 2025
HepTcell™
Top line data in Q1 2024